S Michael Rothenberg
Overview
Explore the profile of S Michael Rothenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
3150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yaeger R, McKean M, Haq R, Beck J, Taylor M, Cohen J, et al.
Cancer Discov
. 2024 May;
14(9):1599-1611.
PMID: 38691346
RAF inhibitors have transformed treatment for patients with BRAFV600-mutant cancers, but clinical benefit is limited by adaptive induction of ERK signaling, genetic alterations that induce BRAFV600 dimerization, and poor brain...
2.
Drilon A, Sharma M, Johnson M, Yap T, Gadgeel S, Nepert D, et al.
Cancer Discov
. 2023 Jun;
13(8):1789-1801.
PMID: 37269335
Significance: PF-07284892-targeted therapy combinations overcame bypass-signaling-mediated resistance in a clinical setting in which neither component was active on its own. This provides proof of concept of the utility of SHP2...
3.
Johnson M, Dudek A, Sukari A, Call J, Kunk P, Lewis K, et al.
Clin Cancer Res
. 2022 Mar;
28(12):2517-2526.
PMID: 35302585
Purpose: ARRY-382 (PF-07265804) is a selective inhibitor of colony-stimulating factor-1 receptor. We evaluated the safety and preliminary efficacy of ARRY-382 plus pembrolizumab in patients with advanced solid tumors. Patients And...
4.
Watanabe S, Takeda M, Otani T, Yoshida T, Sakai K, Olek E, et al.
JCO Precis Oncol
. 2021 May;
5.
PMID: 34036231
No abstract available.
5.
Rosen E, Johnson M, Clifford S, Somwar R, Kherani J, Son J, et al.
Clin Cancer Res
. 2020 Oct;
27(1):34-42.
PMID: 33082208
Purpose: The proto-oncogene encodes a receptor tyrosine kinase that is activated by gene fusion in 1%-2% of non-small cell lung cancers (NSCLC) and rarely in other cancer types. Selpercatinib is...
6.
Ortiz M, Gerdemann U, Govinda Raju S, Henry D, Smith S, Rothenberg S, et al.
JCO Precis Oncol
. 2020 Sep;
4.
PMID: 32923911
No abstract available.
7.
Wirth L, Kohno T, Udagawa H, Matsumoto S, Ishii G, Ebata K, et al.
JCO Precis Oncol
. 2020 Sep;
3.
PMID: 32923848
No abstract available.
8.
Wirth L, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al.
N Engl J Med
. 2020 Aug;
383(9):825-835.
PMID: 32846061
Background: mutations occur in 70% of medullary thyroid cancers, and fusions occur rarely in other thyroid cancers. In patients with -altered thyroid cancers, the efficacy and safety of selective RET...
9.
Drilon A, Oxnard G, Tan D, Loong H, Johnson M, Gainor J, et al.
N Engl J Med
. 2020 Aug;
383(9):813-824.
PMID: 32846060
Background: fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. Methods:...
10.
Kander E, Shah M, Zhou Y, Goyal A, Palmer J, Owen D, et al.
Clin Lung Cancer
. 2020 Jul;
22(3):e442-e445.
PMID: 32660930
No abstract available.